home / stock / xrtx / xrtx news

XRTX News and Press, XORTX Therapeutics Inc. From 09/07/23

Stock Information
Company Name: XORTX Therapeutics Inc.
Stock Symbol: XRTX
Market: NASDAQ
Website: xortx.com
Menu
XRTX XRTX Quote XRTX Short XRTX News XRTX Articles XRTX Message Board
Get XRTX Alerts

News, Short Squeeze, Breakout and More Instantly...
XRTX - XORTX Joins the Kidney Foundation and Kidney March

● In Support of Research for Treating the 4 Million Canadians Who Have Chronic Kidney Disease Today ● CALGARY, Alberta, Sept. 07, 2023 (GLOBE NEWSWIRE) --  XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Fran...
XRTX - XORTX Submits Orphan Drug Designation Application to the European Medicines Agency (EMA) to Treat Progressive Kidney Disease

● XORTX’s Proprietary Formulation of Oxypurinol – XORLO™ – to Treat Progressive Kidney Disease Associated with Autosomal Dominant Polycystic Kidney Disease (ADPKD) ● CALGARY, Alberta, Aug. 29, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc...

XRTX - XORTX Therapeutics names Fairbairn CFO

2023-08-04 17:19:06 ET XORTX Therapeutics ( NASDAQ: XRTX ) has named James Fairbairn as its  chief financial officer, the company said Friday. Fairbairn will  replace Amar Keshri, who left the company effective July 31, 2023. Fa...

XRTX - XORTX Appoints Chief Financial Officer

CALGARY, Alberta, Aug. 04, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney diseas...
XRTX - XORTX appoints James Fairbairn as Interim CFO

2023-06-29 12:19:43 ET In its annual and special meeting of shareholders held on Wednesday, June 28, 2023, XORTX Therapeutics ( NASDAQ: XRTX ) announces appointment James Fairbairn as Interim CFO. Source: Press Release For further details see: XORT...

XRTX - XORTX Announces Results of Annual and Special Meeting of Shareholders

CALGARY, Alberta, June 29, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney diseas...

XRTX - XORTX Reminds Shareholders to Vote ahead of the Proxy Voting Deadline for the Company's Upcoming Annual and Special Meeting of Shareholders

The proxy voting deadline for XORTX shareholders to vote their proxies is 10:00 a.m. (Calgary time) on Monday, June 26, 2023. XORTX’s board of directors recommends shareholders vote FOR the election of all director nominees, FOR the appointment of auditors of the en...
XRTX - XORTX Announces PKD Presentation

CALGARY, Alberta, June 06, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney diseas...

XRTX - XORTX Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Deficiency

CALGARY, Alberta, May 24, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease...

XRTX - XORTX Therapeutics' Xorlo eligible for accelerated approval, confirms FDA

2023-05-04 10:04:37 ET XORTX Therapeutics ( NASDAQ: XRTX ) announced a positive outcome of their recent Type D meeting with the U.S. Food and Drug Administration regarding the accelerated approval of XORLO as a treatment for autosomal dominant polycystic kidney disease ((ADPKD). T...
Previous 10 Next 10